Crossject
PublicCrossject is now publicly traded
The data on this page reflects Crossject's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
May 27, 2026
Company Overview
Crossject operates in Healthcare and is based in France. It was founded in 2001.
Crossject is a specialty pharmaceutical company that develops and manufactures needle-free, pre-filled, single-use auto-injection systems for emergency medical situations.
Sector
Healthcare
AI Layer
Non-AI
Crossject Comparables
Compare Crossject with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurelis | 64% | |
| Micropoint Technologies | 43% | |
| The Materia Company | 33% |
For institutional investors. Book with your work email.
Crossject Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | May 27, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Crossject Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.